The rate of ara-cytosine triphosphate (ara-CTP) accumulation and its retention has been correlated with 1-␤-D-arabinofuranosylcytosine (ara-C)-mediated toxicity and clinical outcome in childhood and adult leukemia. We tested to what extent preincubation with the ribonucleotide reductase inhibitors fludarabine (F-ara-A) and hydroxyurea (HU) enhanced ara-CTP levels in two human myeloid (HL-60, CMK) and two lymphoblastic leukemia cell lines (MOLT-4, BLIN-1) and also in blasts from 28 children with acute leukemia (AML: 14, ALL: 14). Incubation experiments carried out with cell lines showed F-ara-A and HU to be equipotent in increasing ara-CTP levels. The highest increase was observed in HL-60 cells whereas preincubation had no modulatory effect in MOLT-4 cells. Accordingly, modulation of intracellular ara-CTP levels differed between the subtypes of childhood acute leukemia: whereas in T-ALL (five) preincubation with F-ara-A and HU had no effect on intracellular ara-C metabolism, increased ara-CTP levels were seen in some cases of pre-B-ALL (seven). In myelogenous blasts (12) clinically relevant enhancement of ara-C toxification was regularly obtained with both, F-ara-A (1.9-fold) and HU (1.5-fold). In conclusion, our data suggest that combinations of ara-C and ribonucleotide reductase inhibitors are apt to increase ara-CTP levels depending on the individual cell type and its sensitivity towards ara-C modulators. Leukemia (2001) 15, 69-73.
Introduction
The pyrimidine analogue 1-␤-D-arabinofuranosylcytosine (ara-C, cytarabine) plays a central role in the treatment of childhood acute leukemia. In order to exert cytotoxicity via incorporation into DNA with subsequent DNA strand breaks, ara-C must undergo intracellular phosphorylation to its active metabolite ara-cytosine triphosphate (ara-CTP) by a sequence of kinases. 1, 2 Besides, further investigation indicates inhibition of topoisomerase I as an additional mechanism for ara-C cytotoxicity. 3 In clinical studies, cellular accumulation and retention of ara-CTP have been correlated with manifestations of ara-Cmediated cytoxicity and clinical outcome. [4] [5] [6] Resistance against ara-C is the major cause of treatment failure. Mechanistically, resistance can be traced back to any of the various metabolic steps in the toxification pathway to ara-CTP, 7 and partly to a deficiency in deoxycytidine kinase (dCK), the rate limiting enzyme in the ara-C metabolism process. [8] [9] [10] Co-administration of ara-C with ribonucleotide reductase inhibitors such as fludarabine (F-ara-A) and hydroxyurea (HU) constitutes a readily available way to modulate resistance via depleting intracellular dCTP pools and increasing activity of dCK and intracellular ara-CTP levels as a consequence. [11] [12] [13] [14] [15] Since in vitro studies have shown a two-to three-fold increase of ara-CTP levels in AML and CLL blasts, 16 and ALL in adults and children. [18] [19] [20] [21] [22] [23] Data on intracellular ara-C metabolism under these regimens are rare. 18 Notwithstanding the large number of in vitro studies, F-ara-A has never been tested systematically as a modifier of ara-C toxification in different subtypes of acute leukemia, especially in lymphoblastic cells.
The combination of HU, an agent of comparatively low cytotoxicity, 24 and ara-C is rarely used in AML treatment today, although the ability of HU to enhance intracellular ara-CTP was shown in some solid tumors and leukemias in the 1980s. 15, [25] [26] [27] [28] [29] Ara-C modulating potencies of the ribonucleotide reductase inhibitors F-ara-A and HU have hitherto not been compared in a stringent manner. Hence, we determined the enhancement of ara-CTP levels by F-ara-A and HU in the human myeloid leukemia cell lines, HL-60 and CMK, and in the human lymphoblastic leukemia cell lines, MOLT-4 and BLIN-1. Furthermore, we used blasts from 28 children with acute leukemia to test if ara-C toxification differs among various subtypes of leukemia.
Materials and methods

Drugs and materials
F-ara-A, HU, natural nucleotides, and ara-CTP were purchased from Sigma Chemical Co (Deisenhofen, Germany). All chemicals were of the highest purity available.
Ara-C and HU stock solutions were prepared in sterile water, F-ara-A was dissolved in ethanol to obtain final concentrations which did not affect cell growth and viability.
Stock solutions were stored at −20°C. Fetal calf serum (FCS), penicillin, streptomycin, and RPMI 1640 medium containing 2 mM L-glutamine were obtained from GIBCO BRL Life Technologies (Eggenheim, Germany).
Cell culture
HL-60 myeloid leukemia cells 30 and MOLT-4 T-lymphoblastic cells 31 were purchased from the European collection of Cell Cultures (Salisbury, UK). CMK megakaryocytic cells 32 were obtained from the DSMZ, Department of Human and Animal Cell Cultures (Braunschweig, Germany). BLIN-1 pre-B-lymphoblastic cells were first established by Wö rmann et al 33 in 1989. All cell lines tested negative for mycoplasmal infection. Cells were grown in RPMI 1640 medium supplemented with L-glutamine, heat-inactivated FCS (10%), penicillin (100 U/ml), and streptomycin (100 g/ml) in a humidified atmosphere with 5% CO 2 at 37°C. To maintain exponential growth, cells were subcultured every 3 days.
Patients
Patients were treated according to the AML-BFMЈ93 and ALL-BFMЈ95 studies which were approved by the appropriate Insti-Leukemia tutional Review Board. Patients and/or their guardians gave their written informed consent to participate in the study and to the withdrawal of material for diagnostic and further scientific investigations, in accordance with the regulations of the local ethics committee. Blood samples or bone marrow aspirates from pediatric patients were obtained prior to any drug administration as part of routine diagnostic puncture. Leukemic blasts were available from 28 children with AML (12 patients), T-ALL (five patients), pre-B-ALL (seven patients), relapsed acute lymphoblastic leukemia (two patients), and AML as a secondary malignancy (two patients) were examined.
Separation of blast cells
Peripheral blood and bone marrow aspirates were immediate placed on ice, diluted with 15 ml RPMI 1640 medium (GIBCO) and isolated by Ficoll-Hypaque centrifugation (Lymphoprep; Nycomed, Oslo, Norway).
Mononuclear cells at the interface were harvested, washed three times with 50 ml of medium, and centrifuged at 400 g (10 min/4°C).
The total number of blasts was counted and then resuspended in RPMI-1640 with 10% heat-inactivated fetal calf serum (GIBCO) for incubation experiments (37°C). Only samples with у90% blast cells were analyzed.
Cellular pharmacology
Drug concentrations of F-ara-A (5 M), HU (500 M) and ara-C (10 M) were therapeutically relevant and in accordance with the literature. 34 Exponentially growing cells and later on leukemic blast cells were preincubated for 4 h -according to Plunkett et al 14 -either as controls with no drug added or with F-ara-A or HU in a shaking water bath at 37°C followed by 1 h of incubation with ara-C. The incubation time (1 h) and final ara-C concentration (10 M) were in the linear range of ara-CTP accumulation 35 and in accordance with the incubation model used by Gandhi and coworkers. 36 Ara-CTP was extracted using tetrabutyl ammonium hydrogen sulfate and was determined by an isocratic ion pair high performance liquid chromatography (HPLC) method using a reversed phase C18 column (Nova Pak, Waters, Eschborn, Germany) and 0.09 M phosphate puffer (pH 6, tetrahydrofuran 0.35%, tetrabutyl ammonium hydrogen sulfate 0.01 M) with UV detection at 270 nm. The limit of detection was 25 ng/ml ara-CTP. Anthranilic acid was added as internal standard to estimate the total volume of the sample (pellet of known cell count + PTA solution for lysis) and to calculate the extracted number of cells per ml of sample. Ara-CTP levels were expressed as picogram (pg) ara-CTP per 10 7 cells. 37 
Statistical analysis
Incubation and control experiments with cell lines were carried out in triplicate and were repeated at least three times. Intracellular ara-CTP concentrations and proliferation kinetics with and without preincubation with F-ara-A or HU were compared using the paired t-test and expressed as x-fold increase over control.
Results and discussion
Accumulation of ara-CTP in different leukemic cell lines
In 1992, Gandhi et al 34 observed that F-ara-A -in contrast to HU -increased ara-CTP levels in chronic lymphocytic leukemia. The lack of further studies prompted us to determine the enhancement of cellular ara-CTP levels by the ribonucleotide reductase inhibitors, F-ara-A and HU, in different human acute leukemia cell lines and in leukemic blasts from children with various subtypes of acute leukemia. All tests were done using the incubation model that had been applied for the combination of F-ara-A and ara-C in vitro and in vivo. 14, 34, 38 Gandhi et al 17 detected a strong correlation between in vitro and in vivo data. Although absolute rates of ara-CTP accumulation were lower in vitro than those during therapy, the relative capacities were similar. 17 Hence, phenomena observed in vitro would be expected to be transferable to the in vivo situation.
Depending on the cell type, the enhancement of cellular ara-CTP levels by ribonucleotide reductase inhibitors, F-ara-A and HU, differed among the four tested cell lines (Figure 1) .
The highest increase of cellular ara-CTP levels in comparison to non-pretreated cells was observed in the myelogenous HL-60 cells, namely an about 2.8 ± 0.45 (mean ± s.d.)-fold increase by HU and a 2.5 ± 0.42-fold increase by F-ara-A. A similar range of enhanced ara-CTP levels following HU and F-ara-A has previously been described in myeloid cells before. 25, 39 Like Kubota et al 25 who studied ara-C modulation by HU in HL-60 cells and various leukemic B and T lymphoblastic cell lines, we showed that pretreatment with HU did not affect ara-CTP levels in T lymphoblastic MOLT-4 cells. In lymphoblastic pre-B BLIN-1 cells HU pretreatment led to 1.5-fold ara-CTP levels. Kubota and coworkers 25 observed the highest increase of ara-CTP levels in B lymphoblastic cell lines (Raji, Dauji, RPMI-8866, LCL-KIN) and concluded enhancement of ara-CTP levels to be specific to cells of the B cell phenotype. Our results showed augmentation of ara-C toxification by HU in lymphoblastic BLIN-1 cells on a lower level than seen in the incubation results by Kubota. This disparity might partly be attributed to different cell lines and conditions of the incubation models. Like HU, F-ara-A increased cellular ara-CTP levels in BLIN-1 1.5-fold, an effect not observed in Molt-4 cells.
A statistically significant difference (P = 0.05) between Fara-A and HU in augmenting ara-CTP levels was found in
Figure 1
Effect of F-ara-A and HU on ara-CTP levels in four different leukemic cell lines as compared to non-pretreated controls (mean and standard deviation).
Figure 2
Effect of F-ara-A on ara-CTP accumulation in different leukemia subtypes as compared to non-pretreated controls.
CMK cells: pretreatment with F-ara-A resulted in a 2.1 ± 0.18-fold increase of ara-CTP levels, whereas HU increased ara-CTP levels 1.6 ± 0.25-fold. Overall, the difference between Fara-A and HU observed in HL-60, CMK, BLIN-1, and MOLT-4 cells was not statistically significant.
Accumulation of ara-CTP in blasts of different childhood leukemia subtypes
In line with the above-mentioned results, the enhancement of intracellular ara-CTP levels by ribonucleotide reductase inhibitors, F-ara-A and HU, differed clearly between different types of acute leukemia (Figures 2 and 3) .
In AML blasts preincubation with F-ara-A and HU increased ara-CTP accumulation over that of non-pretreated controls, whereas pretreatment had no effect in T-ALL. The difference between these two subtypes of acute leukemia, AML and T-ALL, was statistically significant for both F-ara-A (P Ͻ 0.001) and HU (P = 0.008).
Figure 3
Effect of HU on ara-CTP accumulation in different leukemia subtypes as compared to non-pretreated controls.
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In pre-B-ALL, pretreatment with ribonucleotide reductase inhibitors led to variable results in ara-CTP enhancement. Four out of seven patients showed no significant augmentation of ara-CTP metabolism, whereas the other three patients had a 2.6-fold increase of the cellular ara-CTP levels after preincubation with F-ara-A and a 1.6-fold increase after preincubation with HU.
The combination of F-ara-A and ara-C already undergoes clinical phase I/II testing in the treatment of both adult and childhood relapsed acute leukemia. Nevertheless, studies on cellular ara-CTP levels under these regimens are rare.
The only study on F-ara-A and ara-C in ALL blasts had been carried out by Avramis and coworkers. 18 They found in children with relapsed acute myelogenous and lymphoblastic leukemia (ALL = 13, AML = 18) 5-fold levels of intracellular ara-CTP after in vivo infusion of fludarabine and ex vivo treatment of separated blasts with ara-C (single diagnosis not mentioned). Those three out of seven pre-B-ALL patients who responded to preincubation showed an up to 4-fold increase of ara-CTP levels by F-ara-A and a 2-fold elevation by HU. Looking at these results in blasts from children and in cell lines, the degree of ara-C modulation in lymphocytic cells turns out to be a highly variable phenomenon. Therefore, combination strategies in pre-B-ALL might require a case by case identification via in vitro testing of ara-C modulation in blasts prior to therapy.
In blasts of relapsed ALL, pretreatment with F-ara-A resulted in a 1.9-and 1.5-fold increase of ara-CTP levels, whereas pretreatment with HU resulted in 1.3-and 1.2-fold ara-CTP levels.
In blasts from one patient with secondary AML, cellular ara-CTP levels reached a 1.7-fold increase by F-ara-A and a 1.3-fold increase by HU, whereas ara-CTP levels were not affected by preincubation in the second patient with secondary AML.
Correlation of F-ara-A and HU activity in leukemic blasts
Leukemic blasts from all 28 patients were incubated with both F-ara-A and HU. Looking at ara-CTP enhancement by preincubation with those two ribonucleotide reductase inhibitors, we found activity to be positively correlated with a correlation efficient of 0.82 (Figure 4 ).
Figure 4
Correlation of effect of F-ara-A and HU on ara-CTP accumulation in leukemic blasts from 28 children with acute leukemia (correlation efficient: 0.82).
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Figure 5
Comparison of ara-CTP levels after preincubation with Fara-A and HU in myelogenous blasts.
Comparison between F-ara-A and HU regarding ara-C modulatory efficacy in AML blasts
The blasts cells from the 12 AML patients on preincubation with HU showed a 1.5 ± 0.39-fold ara-CTP accumulation (range: 0.96-2.4) compared to blasts treated with ara-C alone. Preincubation with F-ara-A increased ara-CTP levels 1.9 ± 0.43-fold (range: 0.88-2.4). The results are in agreement with those reported by Gandhi et al, 17 who observed a 1.7-fold increase of ara-CTP accumulation in blasts of adults with relapsed acute myelogenous leukemia after F-ara-A and ara-C treatment in vitro.
In the chosen incubation model, the efficacy of F-ara-A in modifying ara-C cytotoxicity proved to be superior to that of HU, the difference was statistically significant (P = 0.004) ( Figure 5 ). However, one has to be aware that the incubation model had been optimized for F-ara-A. According to the positive correlation between the two modulators, HU might qualify as an equipotent ara-C modifier in myelogenous blasts under different experimental conditions.
In conclusion, combinations of ribonucleotide reductase inhibitors and ara-C regularly increased ara-CTP levels in AML, but not in T-ALL. In pre-B-ALL the pattern was variable.
F-ara-A seemed to be superior to HU in our experiments. Taking into account that the incubation model has been optimized for F-ara-A and considering that the two effects are correlated, HU remains an interesting drug to be developed as an ara-C modulator especially in view of its low rate of toxic side-effects and low costs.
Mechanistic comparisons regarding effects of F-ara-A and HU on dCTP pools, on the incorporation of ara-CTP into DNA, and on the induction of proliferation and apoptosis are subjects for further investigations.
